TrialJournal of cancer research and clinical oncology2020

Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial.

Jingde Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.